Camprehensive and development ct pharmacological treatment of retinopathy of prematurity
Camprehensive and development ct pharmacological treatment of retinopathy of prematurity
批准号:
17591832
负责人:
KUSAKA Shunji
金额:
$2.39万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2007
中文摘要
背景/目标:为探讨早产儿视网膜病变(ROP)的常见模型--小鼠氧诱导视网膜病变(OIR)的临床病程与基因表达模式之间的相关性,将出生后7天(P7)的幼鼠置于75%氧气中5天,诱导C57 BL/6 N小鼠OIR。OIR的临床过程在P12至P21期间用FITC-结合的葡聚糖灌注的视网膜平片上进行评价。结果:TLDA聚类分析显示P12与P13、P16与P17的基因表达模式具有同源性,P12与P13的基因表达模式具有同源性,P16与P17的基因表达模式具有同源性。许多与炎症相关的基因在P12和P13时表达上调,此时中央无血管区和中央血管收缩的程度都是最大的,并且这些基因的上调一直持续到P21。与血管生成相关的几个代表性基因,例如,结论:视网膜外新生血管在视网膜缺血再灌注损伤中的表达与视网膜病变的临床表现密切相关,这些结果将有助于了解视网膜病变的病理机制。
英文摘要
Background/aims : To investigate the correlation between the clinical course and gene expression pattern in murine oxygen-induced retinopathy (OIR), a common model of retinopathy of prematurity (ROP).Methods: OIR was induced in C57BL/6N mice by placing postnatal day 7 (P7) pups in 75% oxygen for 5 days. The clinical course of OIR was evaluated on retinal flat-mounts with FITC-conjugated dextran perfusion from P12 to P21. The expression values of 94 genes, selected by microarray analysis, were determined daily from P12 through P21 by RT-PCR with TagMan (R) low-density array (TLDA) and analyzed by hierarchical clustering.Results: TLDA cluster analysis showed the homology of gene expression pattern between P12 and P13, and between P16 and P17. Many genes associated with inflammation were up-regulated from P12 and P13, when the degrees of both central avascular area and central vasoconstriction were maximal, and the up-regulation of the genes continued to P21. Several representative genes associated with angiogenesis, e.g., vascular endothelial growth factor-A and angiopoietin-2, were most up-regulated at P16 and P17, when extraretinal neovascularization became most noticeable.Conclusion: The gene expression pattern was well-correlated with the clinical presentation in murine OIR. These findings will contribute to understand the pathological condition involved in ROP.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Clinical Studies of Intravitreal Injection of Bevacizumab(Avastin) for Rubeosis Associated With Proliferative Diabetic Retinopathy
玻璃体内注射贝伐单抗(阿瓦斯汀)治疗增殖性糖尿病视网膜病变相关红变的临床研究
DOI:
--
发表时间:
2006
期刊:
影响因子:
--
作者:
[H., Sakaguchi, Y., Oshima, M., Sawa, M., Tsujikawa, F., Gomi, Y., Ikuno, M., Kamei, S., Kusaka, Y., Tano]
通讯作者:
Tano
Systemic and Ocular Adverse Events Following Intravitreal Injection of Bevacizumab.
玻璃体内注射贝伐单抗后的全身和眼部不良事件。
DOI:
--
发表时间:
2007
期刊:
影响因子:
--
作者:
[C, Shima, et al.]
通讯作者:
et al.
DOI:
10.1007/s00417-006-0260-3
发表时间:
2006-10-01
期刊:
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
影响因子:
2.7
作者:
[Morimoto, Takeshi, Fukui, Takehiro, Fujikado, Takashi]
通讯作者:
Fujikado, Takashi
未熟児網膜症 手術に踏み切るタイミング
早产儿视网膜病变:手术时机
DOI:
--
发表时间:
2006
期刊:
臨床眼科 60
影响因子:
--
作者:
[佐藤達彦, 日下俊次]
通讯作者:
日下俊次
DOI:
10.1167/iovs.06-1042
发表时间:
2007-03-01
期刊:
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
影响因子:
4.4
作者:
[Kondo, Hiroyuki, Qin, Minghui, Hayashi, Kenshi]
通讯作者:
Hayashi, Kenshi
共 16 条
Anti-VEGF treatment for severe retinopathy of prematurity
-
批准号:17K11440
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2017
-
负责人:KUSAKA Shunji
-
依托单位:
The role of periostin in the pathogenesis of retinopathy of prematurity (ROP) and the effect of 2 anti-vascular endothelial growth factors in the treatment of ROP
-
批准号:26462654
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.08万
-
财政年份:2014
-
负责人:KUSAKA Shunji
-
依托单位:
Studies on the pathogenesis and anti-VEGF treatment of retinopathy of prematurity
-
批准号:23592597
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.33万
-
财政年份:2011
-
负责人:KUSAKA Shunji
-
依托单位:
Studies on the pathogenesis and development of pharmacological treatment of retinopathy of prematurity
-
批准号:20592041
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2008
-
负责人:KUSAKA Shunji
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于VEGF/VEGFR信号通路探讨自拟创疡膏对慢性创面的作用机制研究
-
批准号:2026JJ80680
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:姜平
-
依托单位:
Decorin调控ADAMTS12 m6A甲基化与IL12B/VEGF免疫互作介导肥胖合并妊娠期糖尿病子代心血管疾病的作用研究
-
批准号:2026JJ81694
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:罗慧
-
依托单位:
协同靶向VE-PTP/VEGF重建胶质母细胞瘤血管稳态的双靶点抑制剂开发与机制研究
-
批准号:JCZRLH202601503
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
RNA 结合蛋白HuR与VEGF-D联合调控舌鳞癌侵袭及转移机制的研究
-
批准号:2026JJ80684
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:龚攀
-
依托单位:
金黄跌打散联合海桐皮汤通过HIF-1α/VEGF通路干预新生血管形成防治软骨损伤的机制研究
-
批准号:2026JJ81074
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:钟炜钰
-
依托单位:
基于蛋白质组学探究VEGF转染的人脐带间充质干细胞改善小鼠急性肝衰竭的机制及验证研究
-
批准号:2026JJ81849
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:陈海鸥
-
依托单位:
化痰通络汤调控PIEZO1/ACSL4/VEGF轴阻断线粒体机械转导增强内皮细胞铁死亡抗性促缺血性中风后血管新生的机制研究
-
批准号:2026JJ81884
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:朱新华
-
依托单位:
IGF2BP2通过m6A甲基化修饰调控VEGF-C转录促进头颈鳞癌淋巴管生成的机制研究
-
批准号:JCZRQNB202600634
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
研究川崎病患者血清中VEGF水平与冠状动脉异常的相关性
-
批准号:2026JJ82691
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:鲁涛
-
依托单位:
养精通络方调控HIF-1α/VEGF信号通路调控“氧化应激-线粒体自噬”促进薄型子宫内膜修复的机制研究
-
批准号:2026JJ82186
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:曾晶
-
依托单位: